Company Overview
Neurovation Labs was founded to develop meaningful solutions to mental health disorders, starting with Post-traumatic Stress Disorder (PTSD). With our science-driven, biomarker-based approach, we are revolutionizing the way PTSD is diagnosed and treated.
Neurovation Labs is developing a targeted, oral treatment for PTSD. This novel medication is designed to regionally inhibit the first putative brain biomarker for PTSD, discovered by our co-founders Drs. Jennifer Perusini and Michael Fanselow. Our small molecule drug discovery program is underway.
Concurrently, Neurovation Labs is developing a novel brain penetrant diagnostic tracer for use in PET scanning and other nuclear imaging techniques. This patented/ patent-pending tracer is designed to target the same PTSD biomarker.
PTSD is a serious condition characterized by debilitating symptoms that interfere with daily life function. The current ineffective diagnostic and treatment options overwhelm healthcare services and cause a huge economic burden; the stigma surrounding PTSD prevents many from seeking proper care at all.
Neurovation Labs is leveraging its biomarker discovery to develop two products that take the guesswork out of diagnosing and treating PTSD. We are committed to developing and commercializing effective, targeted therapies to end the mental health crisis.